Home
The EMA Granted PRIME Designation to CRISPR Therapeutics’ and Vertex Pharmaceuticals’ Product CTX001™ for Severe SCD

The EMA Granted PRIME Designation to CRISPR Therapeutics’ and Vertex Pharmaceuticals’ Product CTX001™ for Severe SCD

Today’s Highlights September 22, 2020

Crispr Therapeutics and Vertex Pharmaceuticals CTX001 Granted PRIME Designation by the EMA
CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals (This content is for paid subscribers.

Please click here to subscribe or here to log in.
Today’s Highlights
, , ,
September 22, 2020

Other Articles